我最初想知道是否 $诺瓦瓦克斯医药(NVAX.US$ 无法开发出KP COVID菌株疫苗,坚持使用JN将是一件坏事,但经过反思,JN谱系似乎仍然占主导地位,因此仍有许多好处(美国食品药品管理局现在希望秋季COVID疫苗以KP.2为目标,但并非所有制造商都能做出调整)
已翻译
![图片](https://sgsnsimg.moomoo.com/sns_client_feed/102286586/20240718/ac234f5f4d62906203dbba361b8f4655.jpg?area=101&is_public=true)
1
已翻译
1
$波音(BA.US$ 嗯,尖刺怎么了?
已翻译
3
2
今天发布的有趣版本分享了更多关于 $美特尔(5DX.SG$医疗服务领域的数字化抱负。价格回到了转向之前的水平,很高兴看到愿景得到发展 https://links.sgx.com/1.0.0/corporate-announcements/17QGG3JJHUHV6XRY/
已翻译
1
$Zogenix(ZGNX.US$ acquisition - up 65% overnight, buy and sell high
1
So in the pharma world today…
$联合利华(英国)(UL.US$ said they won’t bid for $葛兰素史克(GSK.US$ - share price impact on both? I’d have said lower for Unilever because the acquisition would be good for their fundamentals and the market knows it, GSK down because they miss out on billions. Let’s see
$赛诺菲安万特(SNY.US$ and $再生元制药公司(REGN.US$’s Duxipent PRIME 2 study in atopic dermatitis has good data - I guess price goes up
$Zogenix(ZGNX.US$ to be bought by UCB...
$联合利华(英国)(UL.US$ said they won’t bid for $葛兰素史克(GSK.US$ - share price impact on both? I’d have said lower for Unilever because the acquisition would be good for their fundamentals and the market knows it, GSK down because they miss out on billions. Let’s see
$赛诺菲安万特(SNY.US$ and $再生元制药公司(REGN.US$’s Duxipent PRIME 2 study in atopic dermatitis has good data - I guess price goes up
$Zogenix(ZGNX.US$ to be bought by UCB...
还有人想过用这种方式投资吗?看看那天会有哪些好消息影响市场,投资一些公司,把它当作投资组合来对待。今天试试这个 $药品制造商 - 一般(LIST2428.US$股票:
$辉瑞(PFE.US$针对 omicron 的 Plaxovid 结果可能会将其推高
$EQRx(EQRX.US$达到 sugemabalib 的第三阶段终点
$阿斯利康(AZN.US$喜马拉雅研究的详细信息显示操作系统对肝癌有22%的益处
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$Bimzelx 实现...
$辉瑞(PFE.US$针对 omicron 的 Plaxovid 结果可能会将其推高
$EQRx(EQRX.US$达到 sugemabalib 的第三阶段终点
$阿斯利康(AZN.US$喜马拉雅研究的详细信息显示操作系统对肝癌有22%的益处
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$Bimzelx 实现...
已翻译
1
4
Weird - both $艾伯维公司(ABBV.US$ and $辉瑞(PFE.US$ got an atopic dermatitis drug approved today - AbbVie shooting up whilst Pfizer lagging behind
2